EP Patent

EP2489663A1 — Compounds as syk kinase inhibitors

Assigned to Almirall SA · Expires 2012-08-22 · 14y expired

What this patent protects

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase.

USPTO Abstract

The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase.

Drugs covered by this patent

Patent Metadata

Patent number
EP2489663A1
Jurisdiction
EP
Classification
Expires
2012-08-22
Drug substance claim
No
Drug product claim
No
Assignee
Almirall SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.